Information Provided By:
Fly News Breaks for August 4, 2016
RDUS
Aug 4, 2016 | 14:53 EDT
As previously reported, Maxim downgraded Radius Health to Sell from Hold with a $24 price target. Analyst Jason McCarthy believes Radius shares are overvalued and continues to believe that Abaloparatide-SC will likely gain approval in 2017 in both the U.S. and Europe, but faces a mature Forteo market, competition from Biosimilar Forteo in 2018, and patients opting for alternative therapies.
News For RDUS From the Last 2 Days
There are no results for your query RDUS